31 Mar 2023
Assets251.58
Total Income184.81
EBITDA32.98
Profit After Tax32.10
NET Worth127.37
Reserves and Surplus125.79
Total Borrowing73.65
At a glance
Updated 2026-09-09The shares listed at ₹452.00, a 31.78% move from the issue price. Q-Line Biotec is a SME IPO with an issue size of ₹214.48 crore, proposed for listing on NSE SME. The offer opens on 21st May 2026 and closes on 25th May 2026. The issue structure includes a fresh issue of ₹203.74 crore. The current listing schedule points to 29th May 2026.
Issue details
Listing atNSE SME
Issue typeBook Build Issue
Issue size₹214.48 Cr
Fresh issue₹203.74 Cr
Face value₹10
Price band₹326.00–₹343.00
Allotment26th May 2026
Listing29th May 2026
Listing performance
Full performance ↗Issue price₹343.00
Listing price₹452.00
Current price—
Listing gain31.78%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹112.00
GMP / upper price32.65%
Est. listing₹455.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens21st May 2026
Closes25th May 2026
Allotment26th May 2026
Refund27th May 2026
Demat27th May 2026
Listing29th May 2026
Subscription demand
Full bidding ↗QIB123.94×
sHNI81.35×
bHNI117.11×
NII / HNI117.11×
Retail71.44×
Total102.42×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 800 | ₹274,400 |
Company
Use of proceeds
| Object | Amount |
|---|---|
| To meet working capital requirements | ₹93.50 Cr |
| Repayment of certain borrowing availed by the Company, in part or full | ₹90.00 Cr |
| General Corporate Purposes | ₹5.10 Cr |
| Issue Expenses | ₹25.89 Cr |
| Total | ₹214.48 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue236.50₹ Cr · -26.7% vs prior year
EBITDA64.23₹ Cr · -9.9% vs prior year
PAT38.69₹ Cr · +37.5% vs prior year
Assets561.34₹ Cr · +23.2% vs prior year
Net Worth229.16₹ Cr · +20.6% vs prior year
Borrowing243.85₹ Cr · +47.8% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2024
Assets339.25
Total Income206.45
EBITDA37.63
Profit After Tax34.44
NET Worth161.81
Reserves and Surplus160.24
Total Borrowing96.91
31 Mar 2025
Assets455.49
Total Income322.58
EBITDA71.32
Profit After Tax28.13
NET Worth189.95
Reserves and Surplus188.37
Total Borrowing164.95
31 Dec 2025
Assets561.34
Total Income236.50
EBITDA64.23
Profit After Tax38.69
NET Worth229.16
Reserves and Surplus212.89
Total Borrowing243.85
KPIs
| KPI | Mar 31, 2025 | Dec 31, 2025 |
|---|---|---|
| ROE | 23.74% | 16.88% |
| ROCE | 17.66% | 13.32% |
| Debt / Equity | 0.87% | 1.06% |
| RoNW | 23.74% | 16.88% |
| PAT Margin | 8.97% | 16.65% |
| EBITDA Margin | 22.73% | 27.64% |
| Price to Book Value | 2.84 | 2.44 |
Valuation & shareholding
Pre-IPO EPS16.47
Post-IPO EPS22.12
Pre-IPO P/E20.82
Post-IPO P/E15.51
Promoter holding pre96.77%
Promoter holding post67.51%
Market cap₹800.16 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Q-Line Biotech IPO | — | 20.68 x | — | — |
| Abh Healthcare IPO | — | 20.69 x | — | — |
| Credent Connect IPO | — | 153.66 x | — | — |
| H. R. IPO | — | 17.53 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| To meet working capital requirements | ₹93.50 Cr |
| Repayment of certain borrowing availed by the Company, in part or full | ₹90.00 Cr |
| General Corporate Purposes | ₹5.10 Cr |
| Issue Expenses | ₹25.89 Cr |
| Total | ₹214.48 Cr |
Registrar & lead managers
Registrar
Purva Sharegistry (India) Pvt.Ltd.Lead managers
- Hem Securities Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-09.
IPO UPDATE ALERTS
Register for IPO Updates →Track Q-Line Biotec without missing an update
Register for subscription, GMP, allotment and listing notifications.